The MEK/ERK and the PI3K/AKT/mTOR pathways are the classical effectors of RAS, implicated in the regulation of various cellular responses known to generate resistance to CRC therapy [33]. The gene discussed is PIK3CA; the disease is colorectal carcinoma.